Top

Published in:

01-05-2011 | Original Article

Impact of tight control strategy on rheumatoid arthritis in Sarawak

Authors: Cheng Lay Teh, Jin Shyan Wong

Published in: Clinical Rheumatology | Issue 5/2011

Abstract

The aim of our study is to describe the impact of tight control strategy on the care of RA patients in Sarawak General Hospital. We performed a prospective study of all patients with a diagnosis of RA who received treatment at the Rheumatology Clinic in Sarawak General Hospital over a 1-year period. Systematic DAS-driven treatment adjustments aimed to achieve low disease activity (DAS 28-ESR <2.6) were carried out in the clinic over the 1-year period. Disease activity and treatment regimes of all 142 patients were collected for at baseline and 1 year later for statistical analysis. Our patients have a significantly lower DAS 28 with a mean of 2.99 ± 0.95 compared with baseline of 4.31 ± 1.34 (p < 0.000). More patients were in remission 1 year later compared to baseline (36.6% vs 11.3%). Tight control strategy has a positive impact on the care of RA patients in our centre. By optimising the care of RA through tight control strategy, RA can be better controlled in our centre.

Teh CL, Wong JS (2008) The pattern and clinical manifestations of rheumatoid arthritis in Sarawak General Hospital. Clin Rheumatol 27(11):1437–1440, Epub 2008 Sep 5PubMedCrossRef

Klarenbeek NB, Allaart CF, Kerstens PJ, Huizinga TW, Dijkmans BA (2009) The BeSt story: on strategy trials in rheumatoid arthritis. Curr Opin Rheumatol 21(3):291–298PubMedCrossRef

Grigor C, Capell H, Stirling A et al (2004) Effect of a treatment strategy of tight control of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomized controlled trial. Lancet 364:263–269PubMedCrossRef

Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, Nielen MM, Vos K, van Schaardenburg D, Speyer I, Seys PE, Breedveld FC, Allaart CF, Dijkmans BA (2009) (2009) DAS-driven therapy versus routine care in patients with recent-onset active Rheumatoid Arthritis. Ann Rheum Dis 69(1):65–69CrossRef

Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW (2007) Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 66(Suppl 3):iii56–iii60PubMedCrossRef

Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Breedveld FC, Dijkmans BA, FARR study group (2006) Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. Clin Exp Rheumatol 24(6 Suppl 43):S-77–S-82

Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, Blaauw AA, Bijlsma JW, Utrecht Rheumatoid Arthritis Cohort study group (2007) Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66:1443–1449PubMedCrossRef

Fransen J, Moens HB, Speyer I, van Riel PL (2005) Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 64:1294–1298PubMedCrossRef

Katchamart W, Bombardier C (2010) Systematic monitoring of disease activity using an outcome measure improves outcomes in rheumatoid arthritis. J Rheumatol 37(7):1411–1415, Epub 2010 May 1PubMedCrossRef

10.

Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef

11.

Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRef

12.

van Riel PL, van Restel AM (2000) Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis 59(Suppl 1):i28–i31PubMedCrossRef

13.

Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F (1992) The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 35(5):498–502PubMedCrossRef

14.

Health Facts Sarawak 2006. Sarawak State Health Department (Information and Documentation Unit)

15.

Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, Emery P, Ferraccioli G, Hazes JM, Klareskog L, Machold K, Martin-Mola E, Nielsen H, Silman A, Smolen J, Yazici H (2007) EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66(1):34–45, Epub 2006 Jan 5PubMedCrossRef

16.

Sokka T, Kautiainen H, Toloza S et al (2007) QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 66:1491–1496, Epub 2007 Apr 5PubMedCrossRef

17.

Möttönen T, Hannonen P, Korpela M, FIN-RACo Trial Group. FINnish Rheumatoid Arthritis Combination therapy et al (2002) Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 46(4):894–898PubMedCrossRef

18.

Drossaers-Bakker KW, Zwinderman AH, Vliet Vlieland TP, Van Zeben D, Vos K, Breedveld FC, Hazes JM (2002) Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year follow up. Arthritis Rheum 47(4):383–390PubMedCrossRef

19.

van Zeben D, Breedveld FC (1996) Prognostic factors in rheumatoid arthritis. J Rheumatol 44:31–33

20.

Sokka T, Pincus T (2008) Ascendancy of weekly low-dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States. Rheumatology (Oxford) 47(10):1543–1547, Epub 2008 Aug 7CrossRef

21.

Sokka T, Pincus T (2002) Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol 29:2521–2524PubMed

22.

Ward MM, Fries JF (1998) Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981–1996. J Rheumatol 25:408–416PubMed

23.

Mikuls TR (2000) Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981–1996. Arthritis Rheum 43:464–467PubMedCrossRef

24.

Klaukka T, Kaarela K (2003) Methotrexate is the leading DMARD in Finland. Ann Rheum Dis 62:494–496PubMedCrossRef

25.

Saunders SA, Capell HA, Stirling A, Vallance R, Kincaid W, McMahon AD, Porter DR (2008) Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 58(5):1310–1317PubMedCrossRef

26.

O'Dell JR, Leff R, Paulsen G et al (2002) Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(5):1164–1170PubMedCrossRef

27.

Möttönen T, Hannonen P, Leirisalo-Repo M et al (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial FIN-RACo trial group. Lancet 353(9164):1568–1573PubMedCrossRef

28.

Schipper LG, van Hulst LT, Grol R, van Riel PL, Hulscher ME, Fransen J (2010) Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology (Oxford). doi:10.1093/rheumatology/keq195

Title: Impact of tight control strategy on rheumatoid arthritis in Sarawak
Authors: Cheng Lay Teh
Jin Shyan Wong
Publication date: 01-05-2011
Publisher: Springer-Verlag
Published in: Clinical Rheumatology / Issue 5/2011
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-010-1583-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2011

A retrospective analysis of treatment outcomes in patients with hepatitis C related systemic vasculitis receiving intravenous methylprednisolone and cyclophosphamide

Takayasu’s arteritis progression on anti-TNF biologics: a case series

Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis

An independent review of NCCAM-funded studies of chiropractic

Assessment of endothelial function in patients with fibromyalgia—cardiac ultrasound study

Delivery of paediatric rheumatology care in the UK—the projected shortfall

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials